· Pre-clinical studies demonstrate NT-I7’s potential to enhance anti-tumor responses in combination with compounds targeting multiple biological pathways
NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, presented the broad combination potential of its long-acting IL-7 candidate - NT-I7 (efineptakin alfa) (rhIL-7-hyFc) - at the American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, Louisiana, United States, April 8-13 2022.
In the two pre-clinical studies presented as posters, NT-I7, a novel long-acting human IL-7 was evaluated in combination with IL-2 (hIL-2/TCB2c), and in combination with anti-TIGIT or anti-VEGF therapies.
NT-I7 has demonstrated in previous studies that it can increase the number of memory T cells with prolonged effect, whereas IL-2activates the effector T cell for a limited period. The results of the pre-clinical study showed that the combination of their different mechanisms of action (MoAs) created a heightened anti-tumor response.
Additionally, data from the second pre-clinical study showed that NT-I7 in combination with anti-TIGIT or anti-VEGF, enhanced the anti-tumor responses and this effect was further increased when NT-I7 was combined with anti-TIGIT and anti-PD-1 in triple combination.1,2
“Immune Checkpoint Inhibitor combinations have become the standard of care for many tumor types, however there is still an unmet need to enhance the efficacy,” said Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NIT. “The pre-clinical results we presented at AACR 2022, which are supported by NT-I7’s safety profile and T cell amplifying mechanism, showed the potential for NT-I7 as part of a double or triple-regimen therapy. We are encouraged by these results, which pave the way to advance these combinations in clinical trials, further enhancing NT-I7 clinical value.”